BLUE - bluebird bio Stock Trading

A biotech that has been developing new treatments for cancer and cures for severe genetic diseases will soon become a pair of more-focused independent companies. On Monday, bluebird bio (NASDAQ: BLUE) announced its intent to spin off its oncology business. The transition is expe...

Severe Genetic Disease business will remain the focus of bluebird bio, Inc.; separation expected to result in two independent, publicly traded companies by year-end 2021 Separation designed to unlock value through improved operational execution, organizational focus, tailored ...

As the American Society of Hematology conference wrapped up, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discussed the best investments in the hematology space. In this video from Motley Fool Live, recorded on Dec. 14, Brian talks abou...